Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.

Epigenetic plasticity driven by genomic and cytogenetic changes enables therapy resistance and disease progression in multiple myeloma, with nearly 900 patient samples revealing key transitions.

• Why it matters: Understanding how tumor cells adapt to microenvironmental and therapeutic pressures is crucial for developing effective treatments for multiple myeloma, especially as it becomes resistant to therapy.
• What they did: The study analyzed a large cohort of nearly 900 patients, combining molecular and clinical data, and used functional studies in cell models to link chromatin plasticity with therapy resistance and disease evolution.
• The result: Findings suggest that genomic heterogeneity unlocks gene regulatory flexibility, allowing plasma cells to evade treatments, and highlight epigenetic plasticity as a potential therapeutic target in MM.